|
1
|
Maajani K, Jalali A, Alipour S, Khodadost
M, Tohidinik HR and Yazdani K: The global and regional survival
rate of women with breast cancer: A systematic review and
meta-analysis. Clin Breast Cancer. 19:165–177. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shan K, Lincoff AM and Young JB:
Anthracycline-induced cardiotoxicity. Ann Intern Med. 125:47–58.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vejpongsa P and Yeh E: Prevention of
anthracycline-induced cardiotoxicity: Challenges and opportunities.
J Am Coll Cardiol. 64:938–945. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Slamon DJ, Eiermann W, Robert NJ, Giermek
J, Martin M, Mackey J, Chan A, Pinter T, Valero V, Falkson C, et
al: Abstract S5-04: Ten year follow-up of BCIRG-006 comparing
doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with
doxorubicin plus cyclophosphamide followed by docetaxel and
trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab
(TCH) in HER2+early breast cancer. Cancer Res. 76 (Suppl
4):S5-04-S5-04. 2016.
|
|
5
|
Slamon D, Eiermann W, Robert N, Pienkowski
T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et
al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J
Med. 365:1273–1283. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gradishar WJ, Anderson BO, Abraham J, Aft
R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD,
et al: Breast cancer, version 3.2020, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 18:452–478. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Ramshorst MS, van der Voort A, van
Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop
AH, Tick LW, van de Wouw AJ, et al: Neoadjuvant chemotherapy with
or without anthracyclines in the presence of dual HER2 blockade for
HER2-positive breast cancer (TRAIN-2): A multicentre, open-label,
randomised, phase 3 trial. Lancet Oncol. 19:1630–1640. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wadugu B and Kuehn B: The role of
neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on
effects on cardiomyocyte proliferation. Am J Physiol Heart Circ
Physiol. 302:H2139–H2147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rochette L, Guenancia C, Gudjoncik A,
Hachet O, Zeller M, Cottin Y and Vergely C:
Anthracyclines/trastuzumab: New aspects of cardiotoxicity and
molecular mechanisms. Trends Pharmacol Sci. 36:326–348. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Piccart-Gebhart MJ, Procter M,
Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga
J, Bell R, Jackisch C, et al: Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer. N Engl J Med.
353:1659–1672. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Swain SM, Kim SB, Cortés J, Ro J,
Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,
Knott A, et al: Pertuzumab, trastuzumab, and docetaxel for
HER2-positive metastatic breast cancer (CLEOPATRA study): Overall
survival results from a randomised, double-blind,
placebo-controlled, phase 3 study. Lancet Oncol. 14:461–471. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gianni L, Pienkowski T, Im YH, Roman L,
Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J,
Im SA, et al: Efficacy and safety of neoadjuvant pertuzumab and
trastuzumab in women with locally advanced, inflammatory, or early
HER2-positive breast cancer (NeoSphere): A randomised multicentre,
open-label, phase 2 trial. Lancet Oncol. 13:25–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fasching PA, Hartkopf AD, Gass P, Häberle
L, Akpolat-Basci L, Hein A, Volz B, Taran FA, Nabieva N, Pott B, et
al: Efficacy of neoadjuvant pertuzumab in addition to chemotherapy
and trastuzumab in routine clinical treatment of patients with
primary breast cancer: A multicentric analysis. Breast Cancer Res
Treat. 173:319–328. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Valachis A, Nearchou A, Polyzos NP and
Lind P: Cardiac toxicity in breast cancer patients treated with
dual HER2 blockade. Int J Cancer. 133:2245–2252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gianni L, Pienkowski T, Im YH, Tseng LM,
Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA,
Pedrini JL, et al: 5-year analysis of neoadjuvant pertuzumab and
trastuzumab in patients with locally advanced, inflammatory, or
early-stage HER2-positive breast cancer (NeoSphere): A multicentre,
open-label, phase 2 randomised trial. Lancet Oncol. 17:791–800.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rimawi M, Ferrero J, de la Haba-Rodriguez
J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C
and Arpino G; PERTAIN Study Group, : First-line trastuzumab plus an
aromatase inhibitor, with or without pertuzumab, in human epidermal
growth factor receptor 2-positive and hormone receptor-positive
metastatic or locally advanced breast cancer (PERTAIN): A
randomized, open-label phase II trial. J Clin Oncol. 36:2826–2835.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hubalek M, Brantner C and Marth C: Role of
pertuzumab in the treatment of HER2-positive breast cancer. Breast
cancer (Dove Medical Press). 4:65–73. 2012.PubMed/NCBI
|
|
19
|
Cho HS, Mason K, Ramyar KX, Stanley AM,
Gabelli SB, Denney DW Jr and Leahy DJ: Structure of the
extracellular region of HER2 alone and in complex with the
Herceptin Fab. Nature. 421:756–760. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Franklin MC, Carey KD, Vajdos FF, Leahy
DJ, de Vos AM and Sliwkowski MX: Insights into ErbB signaling from
the structure of the ErbB2-pertuzumab complex. Cancer Cell.
5:317–328. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
von Minckwitz G, Huang CS, Mano MS, Loibl
S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A,
Redondo A, et al: Trastuzumab emtansine for residual invasive
HER2-positive breast cancer. N Engl J Med. 380:617–628. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ponde N, Ameye L, Lambertini M, Paesmans
M, Piccart M and de Azambuja E: Trastuzumab emtansine
(T-DM1)-associated cardiotoxicity: Pooled analysis in advanced
HER2-positive breast cancer. Eur J Cancer. 126:65–73. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Geyer CE, Forster J, Lindquist D, Chan S,
Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A,
Kaufman B, et al: Lapatinib plus capecitabine for HER2-positive
advanced breast cancer. N Engl J Med. 355:2733–2743. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hsu W, Huang C, Yen C, Cheng A and Hsieh
P: The HER2 inhibitor lapatinib potentiates doxorubicin-induced
cardiotoxicity through iNOS signaling. Theranostics. 8:3176–3188.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Choi HD and Chang MJ: Cardiac toxicities
of lapatinib in patients with breast cancer and other HER2-positive
cancers: A meta-analysis. Breast Cancer Res Treat. 166:927–936.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li J and Gu J: Cardiovascular toxicities
with vascular endothelial growth factor receptor tyrosine kinase
inhibitors in cancer patients: A meta-analysis of 77 randomized
controlled trials. Clin. Drug Investg. 38:1109–1123. 2018.
View Article : Google Scholar
|
|
27
|
Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde
G and Choueiri TK: QTc interval prolongation with vascular
endothelial growth factor receptor tyrosine kinase inhibitors. Br J
Cancer. 112:296–305. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Borges VF, Ferrario C, Aucoin N, Falkson
C, Khan Q, Krop I, Welch S, Conlin A, Chaves J, Bedard PL, et al:
Tucatinib combined with ado-trastuzumab emtansine in advanced
ERBB2/HER2-positive metastatic breast cancer A phase 1b clinical
trial. JAMA Oncol. 4:1214–1220. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Force T, Krause D and Van Etten R:
Molecular mechanisms of cardiotoxicity of tyrosine kinase
inhibition. Nat Rev Cancer. 7:332–344. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tomasovic A, Brand T, Schanbacher C,
Kramer S, Hümmert MW, Godoy P, Schmidt-Heck W, Nordbeck P, Ludwig
J, Homann S, et al: Interference with ERK-dimerization at the
nucleocytosolic interface targets pathological ERK1/2 signaling
without cardiotoxic Side-effects. Nat Commun. 11:17332020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zamorano JL, Lancellotti P, Rodriguez
Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ,
Lip GYH, Lyon AR, et al: 2016 ESC position paper on cancer
treatments and cardiovascular toxicity developed under the auspices
of the ESC Committee for Practice Guidelines The Task Force for
cancer treatments and cardiovascular toxicity of the European
Society of Cardiology (ESC). Eur Heart J. 19:9–42. 2017. View Article : Google Scholar
|
|
32
|
Nickel AC, Patel A, Saba NF, Leon AR,
El-Chami MF and Merchant FM: Incidence of cancer treatment-induced
arrhythmia associated with novel targeted chemotherapeutic agents.
J The Am Heart Assoc. 7:e0101012018. View Article : Google Scholar
|
|
33
|
Tamargo J, Caballero R and Delpon E:
Cancer chemotherapy and cardiac arrhythmias: A review. Drug Safety.
38:129–152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Herrmann J: Adverse cardiac effects of
cancer therapies: Cardiotoxicity and arrhythmia. Nat Rev Cardiol.
17:474–502. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Curigliano G, Cardinale D, Suter T,
Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch
A, Cipolla C and Roila F; ESMO Guidelines Working Group, :
Cardiovascular toxicity induced by chemotherapy, targeted agents
and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 23
(Suppl 7):S155–S166. 2012. View Article : Google Scholar
|
|
36
|
Lang RM, Badano LP, Mor-Avi V, Afilalo J,
Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA,
Kuznetsova T, et al: Recommendations for cardiac chamber
quantification by echocardiography in adults: An update from the
American Society of Echocardiography and the European Association
of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging.
16:233–271. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mitchell C, Rahko PS, Blauwet LA, Canaday
B, Finstuen JA, Foster MC, Horton K, Ogunyankin KO, Palma RA and
Velazquez EJ: Guidelines for performing a comprehensive
transthoracic echocardiographic examination in Adults:
Recommendations from the American society of echocardiography. J Am
Soc Echocardiogr. 32:1–64. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Thavendiranathan P, Grant AD, Negishi T,
Plana JC, Popovic ZB and Marwick TH: Reproducibility of
echocardiographic techniques for sequential assessment of left
ventricular ejection fraction and volumes application to patients
undergoing cancer chemotherapy. J Am Coll Cardiol. 61:77–84. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dorosz JL, Lezotte DC, Weitzenkamp DA,
Allen LA and Salcedo EE: Performance of 3-dimensional
echocardiography in measuring left ventricular volumes and ejection
fraction: A systematic review and meta-analysis. J Am Coll Cardiol.
59:1799–1808. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nagueh SF, Appleton CP, Gillebert TC,
Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka
PA and Evangelisa A: Recommendations for the evaluation of left
ventricular diastolic function by echocardiography. J Am Soc
Echocardiogr. 22:107–133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fallah-Rad N, Walker JR, Wassef A, Lytwyn
M, Bohonis S, Fang T, Tian G, Kirkpatrick ID, Singal PK, Krahn M,
et al: The utility of cardiac biomarkers, tissue velocity and
strain imaging, and cardiac magnetic resonance imaging in
predicting early left ventricular dysfunction in patients with
human epidermal growth factor receptor II-positive breast cancer
treated with adjuvant trastuzumab therapy. J Am Coll Cardiol.
57:2263–2270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Upshaw JN, Finkelman B, Hubbard RA, Smith
AM, Narayan HK, Arndt L, Domchek S, DeMichele A, Fox K, Shah P, et
al: Comprehensive assessment of changes in left ventricular
diastolic function with contemporary breast cancer therapy. JACC
Cardiovasc Imaging. 13:198–210. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Timoteo AT, Moura Branco L, Filipe F,
Galrinho A, Rio P, Portugal G, Oliveira S and Ferreira RC:
Cardiotoxicity in breast cancer treatment: What about left
ventricular diastolic function and left atrial function?
Echocardiography. 36:1806–1813. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang B, Yu Y, Zhang Y, Hao X, Zhao H, Yang
S, Sun Q and Wang Y: Speckle tracking echocardiography in the early
detection and prediction of anthracycline cardiotoxicity in diffuse
large B-cell lymphoma treated with (R)-CHOP regimen.
Echocardiography. 37:421–428. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Park J, Park J, Park J and Cho G: Global
longitudinal strain to predict mortality in patients with acute
heart failure. J Am Coll Cardiol. 71:1947–1957. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ersbøll M, Valeur N, Mogensen UM, Andersen
MJ, Møller JE, Velazquez EJ, Hassager C, Søgaard P and Køber L:
Prediction of all-cause mortality and heart failure admissions from
global left ventricular longitudinal strain in patients with acute
myocardial infarction and preserved left ventricular ejection
fraction. J Am Coll Cardiol. 61:2365–2373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Laufer-Perl M, Arnold JH, Mor L, Amrami N,
Derakhshesh M, Moshkovits Y, Sadeh B, Arbel Y, Topilsky Y and
Rozenbaum Z: The association of reduced global longitudinal strain
with cancer therapy-related cardiac dysfunction among patients
receiving cancer therapy. Clin Res Cardiol. 109:255–262. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Thavendiranathan P, Poulin F, Lim KD,
Plana JC, Woo A and Marwick TH: Use of myocardial strain imaging by
echocardiography for the early detection of cardiotoxicity in
patients during and after cancer chemotherapy: A sys. J Am Coll
Cardiol. 63:2751–2768. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sawaya H, Sebag IA, Plana JC, Januzzi JL,
Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, et al:
Assessment of Echocardiography and biomarkers for the extended
prediction of cardiotoxicity in patients treated with
anthracyclines, Taxanes, and trastuzumab. Circ Cardiovasc Imaging.
5:596–603. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Santoro C, Esposito R, Lembo M, Sorrentino
R, De Santo I, Luciano F, Casciano O, Giuliano M, De Placido S,
Trimarco B, et al: Strain-oriented strategy for guiding
cardioprotection initiation of breast cancer patients experiencing
cardiac dysfunction. Eur Heart J Cardiovasc Imaging. 20:1345–1352.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bayar N, Küçükseymen S, Göktaş S and
Arslan Ş: Right ventricle failure associated with trastuzumab. Ther
Adv Drug Saf. 6:98–102. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Grover S, Leong DP, Chakrabarty A, Joerg
L, Kotasek D, Cheong K, Joshi R, Joseph MX, DePasquale C, Koczwara
B and Selvanayagam JB: Left and right ventricular effects of
anthracycline and trastuzumab chemotherapy: A prospective study
using novel cardiac imaging and biochemical markers. Int J Cardiol.
168:5465–5467. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zaidi A, Knight DS, Augustine DX, Harkness
A, Oxborough D, Pearce K, Ring L, Robinson S, Stout M, Willis J, et
al: Echocardiographic assessment of the right heart in adults: A
practical guideline from the British Society of Echocardiography.
Echo Res Pract. 7:G19–G41. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Keramida K and Farmakis D: Right
ventricular involvement in cancer therapy-related cardiotoxicity:
The emerging role of strain echocardiography. Heart Fail Rev. Mar
3–2020.(Epub ahead of print). doi: 10.1007/s10741-020-09938-8.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cardinale D, Sandri MT, Colombo A, Colombo
N, Boeri M, Lamantia G, Civelli M, Peccatori F, Martinelli G,
Fiorentini C and Cipolla CM: Prognostic value of troponin I in
cardiac risk stratification of cancer patients undergoing high-dose
chemotherapy. Circulation. 109:2749–2754. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Katsurada K, Ichida M, Sakuragi M,
Takehara M, Hozumi Y and Kario K: High-sensitivity troponin T as a
marker to predict cardiotoxicity in breast cancer patients with
adjuvant trastuzumab therapy. Springerplus. 3:6202014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kistorp C, Raymond I, Pedersen F,
Gustafsson F, Faber J and Hildebrandt P: N-terminal pro-brain
natriuretic peptide, C-reactive protein, and urinary albumin levels
as predictors of mortality and cardiovascular events in older
adults. JAMA. 293:1609–1616. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Romano S, Fratini S, Ricevuto E,
Procaccini V, Stifano G, Mancini M, Di Mauro M, Ficorella C and
Penco M: Serial measurements of NT-proBNP are predictive of
not-high-dose anthracycline cardiotoxicity in breast cancer
patients. Br J Cancer. 105:1663–1668. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ekstein S, Nir A, Rein AJ, Perles Z,
Bar-Oz B, Salpeter L, Algur N and Weintraub M: N-terminal-proB-type
natriuretic peptide as a marker for acute anthracycline
cardiotoxicity in children. J Pediatr Hematol Oncol. 29:440–444.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
van Boxtel W, Bulten BF,
Mavinkurve-Groothuis AM, Bellersen L, Mandigers CM, Joosten LA,
Kapusta L, de Geus-Oei LF and van Laarhoven HW: New biomarkers for
early detection of cardiotoxicity after treatment with docetaxel,
doxorubicin and cyclophosphamide. Biomarkers. 20:143–148. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Demissei BG, Hubbard RA, Zhang L, Smith
AM, Sheline K, McDonald C, Narayan V, Domchek SM, DeMichele A, Shah
P, et al: Changes in cardiovascular biomarkers with breast cancer
therapy and associations with cardiac dysfunction. J Am Heart
Assoc. 9:e0147082020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Michel L, Mincu RI, Mrotzek SM, Korste S,
Neudorf U, Rassaf T and Totzeck M: Cardiac biomarkers for the
detection of cardiotoxicity in childhood cancer-a meta-analysis.
ESC Heart Fail. 7:423–433. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wang Y, Bao L, Chu B, Gao S, Lu M, Shi L,
Fu L, Fang L and Xiang Q: Progressive elevation of NT-ProBNP during
chemotherapy is related to asymptomatic cardiovascular events in
patients with multiple myeloma. Clin Lymphoma Myeloma Leuk.
19:167–176.e1. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Pan W, Yang DH, Yu P and Yu HZ: Comparison
of predictive value of NT-proBNP, sST2 and MMPs in heart failure
patients with different ejection fractions. BMC Cardiovasc Disord.
20:2082020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Aula H, Skyttä T, Tuohinen S, Luukkaala T,
Hämäläinen M, Virtanen V, Raatikainen P, Moilanen E and
Kellokumpu-Lehtinen PL: ST2 levels increased and were associated
with changes in left ventricular systolic function during a
three-year follow-up after adjuvant radiotherapy for breast cancer.
Breast. 49:183–186. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Huang G, Zhai J, Huang X and Zheng D:
Predictive value of soluble ST-2 for changes of cardiac function
and structure in breast cancer patients receiving chemotherapy.
Medicine. 97:e124472018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Frères P, Bouznad N, Servais L, Josse C,
Wenric S, Poncin A, Thiry J, Moonen M, Oury C, Lancellotti P, et
al: Variations of circulating cardiac biomarkers during and after
anthracycline-containing chemotherapy in breast cancer patients.
BMC Cancer. 18:1022018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Putt M, Hahn VS, Januzzi JL, Sawaya H,
Sebag IA, Plana JC, Picard MH, Carver JR, Halpern EF, Kuter I, et
al: Longitudinal changes in multiple biomarkers are associated with
cardiotoxicity in breast cancer patients treated with doxorubicin,
taxanes, and trastuzumab. Clin Chem. 61:1164–1172. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Knight D, Zumbo G, Barcella W, Steeden JA,
Muthurangu V, Martinez-Naharro A, Treibel TA, Abdel-Gadir A,
Bulluck H, Kotecha T, et al: Cardiac structural and functional
consequences of amyloid deposition by cardiac magnetic resonance
and echocardiography and their prognostic roles. JACC. Cardiovasc
Imaging. 12:823–833. 2019.
|
|
70
|
Tak T, Jaekel C, Gharacholou S, Dworak M
and Marshall S: Measurement of ejection fraction by cardiac
magnetic resonance imaging and echocardiography to monitor
doxorubicin-induced cardiotoxicity. Int J Angiol. 29:45–51. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Armstrong G, Plana J, Zhang N, Srivastava
D, Green DM, Ness KK, Daniel Donovan F, Metzger ML, Arevalo A,
Durand JB, et al: Screening adult survivors of childhood cancer for
cardiomyopathy: Comparison of echocardiography and cardiac magnetic
resonance imaging. J Clin Oncol. 30:2876–2884. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Schneeweiss A, Chia S, Hickish T, Harvey
V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ackrill A, et al:
Neoadjuvant pertuzumab and trastuzumab concurrent or sequential
with an anthracycline-containing or concurrent with an
anthracycline-free standard regimen: A randomized phase II study
(TRYPHAENA). Cancer Res. 71 (Suppl 24):S5–S6. 2011.
|
|
73
|
Du XL, Xia R, Burau K and Liu CC: Cardiac
risk associated with the receipt of anthracycline and trastuzumab
in a large nationwide cohort of older women with breast cancer,
1998–2005. Med Oncol. 28 (Suppl 1):S80–S90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zamorano J, Lancellotti P, Rodriguez Muñoz
D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip
GYH, Lyon AR, et al: 2016 ESC Position Paper on cancer treatments
and cardiovascular toxicity developed under the auspices of the ESC
Committee for Practice Guidelines: The Task Force for cancer
treatments and cardiovascular toxicity of the European Society of
Cardiology (ESC). Eur Heart J. 37:2768–2801. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Armenian SH, Lacchetti C, Barac A, Carver
J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M,
et al: Prevention and monitoring of cardiac dysfunction in
survivors of adult cancers: American Society of Clinical Oncology
Clinical Practice Guideline. J Clin Oncol. 35:893–911. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Plana JC, Galderisi M, Barac A, Ewer MS,
Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP,
et al: Expert consensus for multimodality imaging evaluation of
adult patients during and after cancer therapy: A report from the
American Society of Echocardiography and the European Association
of Cardiovascular Imaging. J Am Soc Echocardiogr. 27:911–939. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Loap P, Kirov K and Kirova Y:
Cardiotoxicity in breast cancer patients treated with radiation
therapy: From evidences to controversies. Crit Rev Oncol Hematol.
156:1031212020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Common Terminology Criteria for Adverse
Events (CTCAE) Version 5.0 Published, Nov 27, 2017. simplehttps://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5×11.pdf
|
|
79
|
Zipes DP, Camm AJ, Borggrefe M, Buxton AE,
Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ,
et al: ACC/AHA/ESC 2006 Guidelines for management of patients with
ventricular arrhythmias and the prevention of sudden cardiac death
a report of the American College of Cardiology/American Heart
Association Task Force and the European Society of Cardiology
Committee for practice Guidelines (Writing Committee to Develop
Guidelines for management of patients with ventricular arrhythmias
and the prevention of Sudden Cardiac Death): Developed in
Collaboration with the European Heart Rhythm Association and the
Heart Rhythm Society. Circulation. 114:e385–e484. 2006. View Article : Google Scholar : PubMed/NCBI
|
